Table 1.
Baseline Characteristics of Adolescents With Perinatally Acquired HIV by Measles Immunity
| Measles Nonimmune by PRN Assay | Measles Immune by PRN Assay | P Valuea | |
|---|---|---|---|
| n = 28 | n = 6 | ||
| Age, years (median) (IQR) | 19 (17–20) | 14.5 (13–18) | P = .01 |
| Female, No. (%) | 19 (65%) | 3 (50%) | P = .648 |
| Race, No. (%) | P = .802 | ||
| White | 1 (4%) | 0 (0%) | |
| African American | 7 (24%) | 1 (17%) | |
| Hispanic | 16 (55%) | 3 (50%) | |
| Other | 5 (17%) | 2 (33%) | |
| History of opportunistic infections, No. (%) | 18 (62%) | 1 (17%) | P = .07 |
| CD4+ cells/mm3 at enrollment (median) (IQR) | 263 (161–378) | 682 (255–1166) | P = .054 |
| Nadir CD4+ cells/mm3 (median) (IQR) | 143 (23–231) | 299 (34–442) | P = .175 |
| Nadir CD4+ cells < 200 cells/mm3, No. (%) | 20 (69%) | 2 (33%) | P = .166 |
| Nadir CD4% (median, IQR) | 14 (3–25) | 25 (7–41) | P = .227 |
| Nadir CD4% <15, No. (%) | 14 (48%) | 2 (33%) | P = .666 |
| HIV RNA log10 (copies/mL) at CD4 nadir (mean) (95% CI) | 3.97 (3.42–4.53) | 3.64 (2.24–5.03) | P = .65 |
| HIV RNA log10 (copies/mL) at enrollment (mean) (95% CI) | 3.74 (3.18–4.3) | 2.79 (1.22–4.36) | P = .159 |
| On cART at enrollment, No. (%) | 21 (75%) | 4 (67%) | P = .645 |
| MMR vaccinations (median) (range) | 2 (1–4) | 2 (2–3) | P = .618 |
| Age at first MMR, months (median) (IQR) | 12 (11–18) | 13.5 (11–15) | P = .873 |
| On ART at time of first MMR, No. (%) | 8 (30%) | 5 (83%) | P = .025 |
| On ART at time of second MMR, No. (%) | 19 (79%) | 6 (100%) | P = .553 |
| Time since last MMR vaccination, years (median) (IQR) | 13.5 (10.8–15) | 7.5 (6–9) | P = .003 |
Abbreviations: ART, antiretroviral therapy; cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IQR, interquartile range; MMR, measles, mumps, rubella; PRN, plaque reduction neutralization.
aP values from t test or Wilcoxon test for continuous variables and χ2 test or Fisher's exact test for categorical variables.